|
시장보고서
상품코드
1831683
신경학 임상시험 시장, 규모, 점유율, 동향, 산업 분석 보고서 : 단계별, 시험디자인별, 적응증별, 밸류체인별, 지역별, 예측(2025-2034년)Neurology Clinical Trials Market Size, Share, Trends, Industry Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design, By Indication, By Value Chain, By Region - Market Forecast, 2025-2034 |
||||||
Polaris Market Research의 최신 조사에 따르면 세계 신경학 임상시험 시장 규모는 2034년까지 105억 9,000만 달러에 달할 전망입니다. 이 설문조사 보고서는 현재 시장 역학을 자세히 파악하고 향후 시장 성장에 대한 분석을 제공합니다.
신경학 임상시험 시장에는 신경계의 상태를 치료하기 위해 고안된 신약, 치료법, 의료기기의 연구 개발이 포함됩니다. 여기에는 알츠하이머병, 파킨슨병, 간질, 뇌졸중 등 뇌, 척수, 말초 신경에 영향을 미치는 광범위한 질병 및 장애가 포함됩니다. 이러한 임상시험의 주요 목적은 새로운 치료법의 안전성과 효능을 검증하고 규제 당국의 승인에 필요한 데이터를 제공함으로써 새로운 치료법을 일반적으로 이용할 수 있도록 하는 것입니다.
시장의 성장은 임상시험기술과 서비스와 함께 신경질환을 앓고 있는 환자수가 전 세계적으로 증가하고 있는 것이 큰 요인이 되고 있습니다. 이러한 질병 부담 증가는 많은 질병에 대한 치료 옵션이 제한적이거나 효과가 없는 경우가 많으며 새로운 치료에 대한 강한 수요를 창출하고 있습니다. 그 결과, 관민 양부문으로부터의 투자 확대에 힘입어 많은 연구개발이 이루어지고 있습니다. 시장 개요를 보면 기존의 의약품 개발과 유전자 치료나 맞춤형 의료와 같은 새롭고 보다 전문적인 치료법 모두에 중점을 두고 있어 복잡하고 경쟁이 심한 분야임을 알 수 있습니다.
신경학 임상시험 시장 보고서 하이라이트
단계별로, 단계 III 시험은 2024년 신경학 임상시험 시장에서 가장 큰 점유율을 차지했습니다.
시험 설계별로는 개입 시험이 2024년에 가장 큰 점유율을 차지했습니다. 이것은 참가자에게 특정 치료를 실시하고 그 효과를 직접 측정하는 이러한 시험이 신약과 의료기기를 시험하는 표준 방법이라는 사실 때문입니다.
적응증별로 알츠하이머병 분야는 2024년에 가장 큰 점유율을 차지했습니다. 이는 이 질환의 환자수가 많아 효과적인 치료법이 세계적으로 급무가 되고 있기 때문입니다.
밸류체인별로는 2024년 자사시장이 최대 점유율을 차지했습니다. 많은 주요 제약 회사와 생명 공학 회사는 임상시험의 전체 프로세스를 자체 관리하기위한 내부 자원, 전문 지식 및 자금을 보유하고 있으며, 자체적으로 완벽하게 관리하고 연구 품질을 보장합니다.
지역별로는 북미가 2024년 신경학 임상시험 시장에서 가장 큰 점유율을 차지했습니다. 이는 의료제도가 발달하고 있는 것, 주요 제약기업이나 바이오테크놀러지 기업이 집중하고 있는 것, 신경질환의 연구개발 자금이 많다는 것에 따릅니다. 아시아태평양은 신경 질환의 임상시험 시장으로 급성장하고 있습니다. 이 지역의 성장의 원동력이 되고 있는 것은 환자수가 많아 다양성이 풍부하기 때문에 임상시험을 위한 환자 모집이 효율적이고 비용대비효율이 높다는 것입니다.
이 시장의 주요 기업으로는 IQVIA, ICON plc, Syneos Health, Laboratory Corporation of America Holdings, Charles River Laboratories, Thermo Fisher Scientific, Parexel, Medpace Holdings, and pharmaceutical companies like Pfizer, Biogen, and Eisai Co. 등이 있습니다.
목차
제1장 서론
제2장 주요 요약
제3장 조사 방법
제4장 세계의 신경학 임상시험 시장 인사이트
- 시장 현황
- 신경학 임상시험 시장 역학
- 성장 촉진요인과 기회
- 신경질환의 유병률 상승
- 정부의 자금과 지원 증가
- 억제요인과 과제
- 복잡성에 의한 높은 시험 실패율
- 성장 촉진요인과 기회
- PESTEL 분석
- 신경학 임상시험 시장 동향
- 밸류체인 분석
- COVID-19의 영향 분석
제5장 세계의 신경학 임상시험 시장 : 위상별
- 주요 조사 결과
- 소개
- 단계 I
- 단계 II
- 단계 III
- 단계 IV
제6장 세계의 신경학 임상시험 시장 : 시험 디자인별
- 주요 조사 결과
- 소개
- 개입적
- 관찰적
- 확장 액세스
제7장 세계의 신경학 임상시험 시장 : 적응증별
- 주요 조사 결과
- 소개
- 알츠하이머병
- 우울증(MDD)
- 파킨슨병(PD)
- 간질
- 뇌졸중
- 외상성 뇌손상(TBI)
- 근위축성 측삭 경화증(ALS)
- 헌팅턴병
- 근육 재생
- 기타
제8장 세계의 신경학 임상시험 시장 : 밸류체인별
- 주요 조사 결과
- 소개
- 사내
- CRO
- 임상시험기관 / 시험책임자 기관
제9장 세계의 신경학 임상시험 시장 : 지역
- 주요 조사 결과
- 소개
- 신경학 임상시험 시장 평가 : 지역, 2020-2034년
- 북미
- 북미 : 단계별, 2020-2034년
- 북미 : 시험 디자인별, 2020-2034년
- 북미 : 적응증별, 2020-2034년
- 북미 : 밸류 체인별, 2020-2034년
- 미국
- 캐나다
- 유럽
- 유럽 : 단계별, 2020-2034년
- 유럽 : 시험 디자인별, 2020-2034년
- 유럽 : 적응증별, 2020-2034년
- 유럽: 밸류체인별, 2020-2034년
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
- 아시아태평양
- 아시아태평양 : 위상별, 2020-2034년
- 아시아태평양 : 시험 디자인별, 2020-2034년
- 아시아태평양 : 적응증별, 2020-2034년
- 아시아태평양 : 밸류 체인별, 2020-2034년
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
- 중동 및 아프리카
- 중동 및 아프리카 : 단계별, 2020-2034년
- 중동 및 아프리카 : 시험 디자인별, 2020-2034년
- 중동 및 아프리카 : 적응증별, 2020-2034년
- 중동 및 아프리카 : 밸류체인별, 2020-2034년
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 남아프리카
- 기타 중동 및 아프리카
- 라틴아메리카
- 라틴아메리카 : 단계별, 2020-2034년
- 라틴아메리카 : 시험 디자인별, 2020-2034년
- 라틴아메리카 : 적응증별, 2020-2034년
- 라틴아메리카 : 밸류체인별, 2020-2034년
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카
제10장 경쟁 구도
- 확대 및 인수 분석
- 확대
- 인수
- 제휴/협업/합의/공개
제11장 기업 프로파일
- Biogen
- Charles River Laboratories
- Eisai Co., Ltd.
- ICON plc
- IQVIA
- Laboratory Corporation of America Holdings
- Medpace Holdings, Inc.
- Parexel
- Pfizer Inc.
- Syneos Health
- Thermo Fisher Scientific
The global neurology clinical trials market size is expected to reach USD 10.59 billion by 2034, according to a new study by Polaris Market Research. The report "Neurology Clinical Trials Market Size, Share, Trends, Industry Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design, By Indication, By Value Chain, By Region - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The neurology clinical trials market involves the research and development of new drugs, therapies, and medical devices designed to treat conditions of the nervous system. This includes a wide range of diseases and disorders affecting the brain, spinal cord, and peripheral nerves, such as Alzheimer's, Parkinson's, epilepsy, and stroke. The main goal of these trials is to test the safety and effectiveness of new treatments, providing the necessary data for regulatory approval so that new therapies can become available to the public.
The market's growth is largely driven by the increasing number of people worldwide who are affected by neurological disorders, along with clinical trial technology and services. This rising disease burden, combined with the often limited or ineffective treatment options for many conditions, creates a strong demand for new therapies. As a result, there is a lot of research and development happening, supported by growing investments from both private and public sectors. The market's overview shows that it is a complex and competitive field, with a focus on both traditional drug development and newer, more specialized treatments like gene therapies and personalized medicine.
Neurology Clinical Trials Market Report Highlights:
By phase, the phase III segment held the largest share of the neurology clinical trials market in 2024 as these trials are the final and most extensive step before a drug can be submitted for regulatory approval.
By study design, the interventional studies segment held the largest share in 2024. This is due to the fact that these trials are the standard method for testing new drugs and medical devices, as they involve giving a specific treatment to participants and directly measuring its effects.
By indication, the Alzheimer's disease segment held the largest share in 2024. This is because of the large number of people affected by this condition and the urgent global need for effective treatments.
By value chain, the in-house segment held the largest share in 2024 of the market. Many large pharmaceutical and biotech companies have the internal resources, expertise, and funding to manage their entire clinical trial process themselves, giving them full control and ensuring the quality of their research.
By region, North America held the largest share of the neurology clinical trials market in 2024. This is due to its well-developed healthcare system, a high concentration of key pharmaceutical and biotechnology companies, and a significant amount of research and development funding for neurological disorders. The Asia Pacific is a rapidly growing market for neurology clinical trials. The region's growth is driven by its large and diverse patient population, which makes patient recruitment for trials more efficient and cost-effective.
A few key players in the market include IQVIA, ICON plc, Syneos Health, Laboratory Corporation of America Holdings, Charles River Laboratories, Thermo Fisher Scientific, Parexel, Medpace Holdings, and pharmaceutical companies like Pfizer, Biogen, and Eisai Co.
Polaris Market Research has segmented the neurology clinical trials market report based on phase, study design, indication, value chain, and region:
By Phase Outlook (Revenue - USD Billion, 2020-2034)
Phase I
Phase II
Phase III
Phase IV
By Study Design Outlook (Revenue - USD Billion, 2020-2034)
Interventional
Observational
Expanded Access
By Indication Outlook (Revenue - USD Billion, 2020-2034)
Alzheimer's Disease
Depression (MDD)
Parkinson's Disease (PD)
Epilepsy
Stroke
Traumatic Brain Injury (TBI)
Amyotrophic Lateral Sclerosis (ALS)
Huntington's Disease
Muscle Regeneration
Others
By Value Chain Outlook (Revenue - USD Billion, 2020-2034)
In-house
CROs
Investigator Sites/Clinical Sites
By Regional Outlook (Revenue - USD Billion, 2020-2034)
North America
U.S.
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Neurology Clinical Trials Market Insights
- 4.1. Neurology Clinical Trials Market - Market Snapshot
- 4.2. Neurology Clinical Trials Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Rising Prevalence of Neurological Disorders
- 4.2.1.2. Increase in Government Funding and Support
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High trial failure rates due to the complexity
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Neurology Clinical Trials Market Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Neurology Clinical Trials Market, by Phase
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Neurology Clinical Trials Market, by Phase, 2020-2034 (USD Billion)
- 5.3. Phase I
- 5.3.1. Global Neurology Clinical Trials Market, by Phase I, by Region, 2020-2034 (USD Billion)
- 5.4. Phase II
- 5.4.1. Global Neurology Clinical Trials Market, by Phase II, by Region, 2020-2034 (USD Billion)
- 5.5. Phase III
- 5.5.1. Global Neurology Clinical Trials Market, by Phase III, by Region, 2020-2034 (USD Billion)
- 5.6. Phase IV
- 5.6.1. Global Neurology Clinical Trials Market, by Phase IV, by Region, 2020-2034 (USD Billion)
6. Global Neurology Clinical Trials Market, by Study Design
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Neurology Clinical Trials Market, by Study Design, 2020-2034 (USD Billion)
- 6.3. Interventional
- 6.3.1. Global Neurology Clinical Trials Market, by Interventional, by Region, 2020-2034 (USD Billion)
- 6.4. Observational
- 6.4.1. Global Neurology Clinical Trials Market, by Observational, by Region, 2020-2034 (USD Billion)
- 6.5. Expanded Access
- 6.5.1. Global Neurology Clinical Trials Market, by Expanded Access, by Region, 2020-2034 (USD Billion)
7. Global Neurology Clinical Trials Market, by Indication
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Neurology Clinical Trials Market, by Indication, 2020-2034 (USD Billion)
- 7.3. Alzheimer's Disease
- 7.3.1. Global Neurology Clinical Trials Market, by Alzheimer's Disease, by Region, 2020-2034 (USD Billion)
- 7.4. Depression (MDD)
- 7.4.1. Global Neurology Clinical Trials Market, by Depression (MDD), by Region, 2020-2034 (USD Billion)
- 7.5. Parkinson's Disease (PD)
- 7.5.1. Global Neurology Clinical Trials Market, by Parkinson's Disease (PD), by Region, 2020-2034 (USD Billion)
- 7.6. Epilepsy
- 7.6.1. Global Neurology Clinical Trials Market, by Epilepsy, by Region, 2020-2034 (USD Billion)
- 7.7. Stroke
- 7.7.1. Global Neurology Clinical Trials Market, by Stroke, by Region, 2020-2034 (USD Billion)
- 7.8. Traumatic Brain Injury (TBI)
- 7.8.1. Global Neurology Clinical Trials Market, by Traumatic Brain Injury (TBI), by Region, 2020-2034 (USD Billion)
- 7.9. Amyotrophic Lateral Sclerosis (ALS)
- 7.9.1. Global Neurology Clinical Trials Market, by Amyotrophic Lateral Sclerosis (ALS), by Region, 2020-2034 (USD Billion)
- 7.10. Huntington's Disease
- 7.10.1. Global Neurology Clinical Trials Market, by Huntington's Disease, by Region, 2020-2034 (USD Billion)
- 7.11. Muscle Regeneration
- 7.11.1. Global Neurology Clinical Trials Market, by Muscle Regeneration, by Region, 2020-2034 (USD Billion)
- 7.12. Others
- 7.12.1. Global Neurology Clinical Trials Market, by Others, by Region, 2020-2034 (USD Billion)
8. Global Neurology Clinical Trials Market, by Value Chain
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Global Neurology Clinical Trials Market, by Value Chain, 2020-2034 (USD Billion)
- 8.3. In-house
- 8.3.1. Global Neurology Clinical Trials Market, by In-house, by Region, 2020-2034 (USD Billion)
- 8.4. CROs
- 8.4.1. Global Neurology Clinical Trials Market, by CROs, by Region, 2020-2034 (USD Billion)
- 8.5. Investigator Sites/Clinical Sites
- 8.5.1. Global Neurology Clinical Trials Market, by Investigator Sites/Clinical Sites, by Region, 2020-2034 (USD Billion)
9. Global Neurology Clinical Trials Market, by Geography
- 9.1. Key Findings
- 9.2. Introduction
- 9.2.1. Neurology Clinical Trials Market Assessment, By Geography, 2020-2034 (USD Billion)
- 9.3. Neurology Clinical Trials Market - North America
- 9.3.1. North America: Neurology Clinical Trials Market, by Phase, 2020-2034 (USD Billion)
- 9.3.2. North America: Neurology Clinical Trials Market, by Study Design, 2020-2034 (USD Billion)
- 9.3.3. North America: Neurology Clinical Trials Market, by Indication, 2020-2034 (USD Billion)
- 9.3.4. North America: Neurology Clinical Trials Market, by Value Chain, 2020-2034 (USD Billion)
- 9.3.5. Neurology Clinical Trials Market - US
- 9.3.5.1. US: Neurology Clinical Trials Market, by Phase, 2020-2034 (USD Billion)
- 9.3.5.2. US: Neurology Clinical Trials Market, by Study Design, 2020-2034 (USD Billion)
- 9.3.5.3. US: Neurology Clinical Trials Market, by Indication, 2020-2034 (USD Billion)
- 9.3.5.4. US: Neurology Clinical Trials Market, by Value Chain, 2020-2034 (USD Billion)
- 9.3.6. Neurology Clinical Trials Market - Canada
- 9.3.6.1. Canada: Neurology Clinical Trials Market, by Phase, 2020-2034 (USD Billion)
- 9.3.6.2. Canada: Neurology Clinical Trials Market, by Study Design, 2020-2034 (USD Billion)
- 9.3.6.3. Canada: Neurology Clinical Trials Market, by Indication, 2020-2034 (USD Billion)
- 9.3.6.4. Canada: Neurology Clinical Trials Market, by Value Chain, 2020-2034 (USD Billion)
- 9.4. Neurology Clinical Trials Market - Europe
- 9.4.1. Europe: Neurology Clinical Trials Market, by Phase, 2020-2034 (USD Billion)
- 9.4.2. Europe: Neurology Clinical Trials Market, by Study Design, 2020-2034 (USD Billion)
- 9.4.3. Europe: Neurology Clinical Trials Market, by Indication, 2020-2034 (USD Billion)
- 9.4.4. Europe: Neurology Clinical Trials Market, by Value Chain, 2020-2034 (USD Billion)
- 9.4.5. Neurology Clinical Trials Market - UK
- 9.4.5.1. UK: Neurology Clinical Trials Market, by Phase, 2020-2034 (USD Billion)
- 9.4.5.2. UK: Neurology Clinical Trials Market, by Study Design, 2020-2034 (USD Billion)
- 9.4.5.3. UK: Neurology Clinical Trials Market, by Indication, 2020-2034 (USD Billion)
- 9.4.5.4. UK: Neurology Clinical Trials Market, by Value Chain, 2020-2034 (USD Billion)
- 9.4.6. Neurology Clinical Trials Market - France
- 9.4.6.1. France: Neurology Clinical Trials Market, by Phase, 2020-2034 (USD Billion)
- 9.4.6.2. France: Neurology Clinical Trials Market, by Study Design, 2020-2034 (USD Billion)
- 9.4.6.3. France: Neurology Clinical Trials Market, by Indication, 2020-2034 (USD Billion)
- 9.4.6.4. France: Neurology Clinical Trials Market, by Value Chain, 2020-2034 (USD Billion)
- 9.4.7. Neurology Clinical Trials Market - Germany
- 9.4.7.1. Germany: Neurology Clinical Trials Market, by Phase, 2020-2034 (USD Billion)
- 9.4.7.2. Germany: Neurology Clinical Trials Market, by Study Design, 2020-2034 (USD Billion)
- 9.4.7.3. Germany: Neurology Clinical Trials Market, by Indication, 2020-2034 (USD Billion)
- 9.4.7.4. Germany: Neurology Clinical Trials Market, by Value Chain, 2020-2034 (USD Billion)
- 9.4.8. Neurology Clinical Trials Market - Italy
- 9.4.8.1. Italy: Neurology Clinical Trials Market, by Phase, 2020-2034 (USD Billion)
- 9.4.8.2. Italy: Neurology Clinical Trials Market, by Study Design, 2020-2034 (USD Billion)
- 9.4.8.3. Italy: Neurology Clinical Trials Market, by Indication, 2020-2034 (USD Billion)
- 9.4.8.4. Italy: Neurology Clinical Trials Market, by Value Chain, 2020-2034 (USD Billion)
- 9.4.9. Neurology Clinical Trials Market - Spain
- 9.4.9.1. Spain: Neurology Clinical Trials Market, by Phase, 2020-2034 (USD Billion)
- 9.4.9.2. Spain: Neurology Clinical Trials Market, by Study Design, 2020-2034 (USD Billion)
- 9.4.9.3. Spain: Neurology Clinical Trials Market, by Indication, 2020-2034 (USD Billion)
- 9.4.9.4. Spain: Neurology Clinical Trials Market, by Value Chain, 2020-2034 (USD Billion)
- 9.4.10. Neurology Clinical Trials Market - Netherlands
- 9.4.10.1. Netherlands: Neurology Clinical Trials Market, by Phase, 2020-2034 (USD Billion)
- 9.4.10.2. Netherlands: Neurology Clinical Trials Market, by Study Design, 2020-2034 (USD Billion)
- 9.4.10.3. Netherlands: Neurology Clinical Trials Market, by Indication, 2020-2034 (USD Billion)
- 9.4.10.4. Netherlands: Neurology Clinical Trials Market, by Value Chain, 2020-2034 (USD Billion)
- 9.4.11. Neurology Clinical Trials Market - Russia
- 9.4.11.1. Russia: Neurology Clinical Trials Market, by Phase, 2020-2034 (USD Billion)
- 9.4.11.2. Russia: Neurology Clinical Trials Market, by Study Design, 2020-2034 (USD Billion)
- 9.4.11.3. Russia: Neurology Clinical Trials Market, by Indication, 2020-2034 (USD Billion)
- 9.4.11.4. Russia: Neurology Clinical Trials Market, by Value Chain, 2020-2034 (USD Billion)
- 9.4.12. Neurology Clinical Trials Market - Rest of Europe
- 9.4.12.1. Rest of Europe: Neurology Clinical Trials Market, by Phase, 2020-2034 (USD Billion)
- 9.4.12.2. Rest of Europe: Neurology Clinical Trials Market, by Study Design, 2020-2034 (USD Billion)
- 9.4.12.3. Rest of Europe: Neurology Clinical Trials Market, by Indication, 2020-2034 (USD Billion)
- 9.4.12.4. Rest of Europe: Neurology Clinical Trials Market, by Value Chain, 2020-2034 (USD Billion)
- 9.5. Neurology Clinical Trials Market - Asia Pacific
- 9.5.1. Asia Pacific: Neurology Clinical Trials Market, by Phase, 2020-2034 (USD Billion)
- 9.5.2. Asia Pacific: Neurology Clinical Trials Market, by Study Design, 2020-2034 (USD Billion)
- 9.5.3. Asia Pacific: Neurology Clinical Trials Market, by Indication, 2020-2034 (USD Billion)
- 9.5.4. Asia Pacific: Neurology Clinical Trials Market, by Value Chain, 2020-2034 (USD Billion)
- 9.5.5. Neurology Clinical Trials Market - China
- 9.5.5.1. China: Neurology Clinical Trials Market, by Phase, 2020-2034 (USD Billion)
- 9.5.5.2. China: Neurology Clinical Trials Market, by Study Design, 2020-2034 (USD Billion)
- 9.5.5.3. China: Neurology Clinical Trials Market, by Indication, 2020-2034 (USD Billion)
- 9.5.5.4. China: Neurology Clinical Trials Market, by Value Chain, 2020-2034 (USD Billion)
- 9.5.6. Neurology Clinical Trials Market - India
- 9.5.6.1. India: Neurology Clinical Trials Market, by Phase, 2020-2034 (USD Billion)
- 9.5.6.2. India: Neurology Clinical Trials Market, by Study Design, 2020-2034 (USD Billion)
- 9.5.6.3. India: Neurology Clinical Trials Market, by Indication, 2020-2034 (USD Billion)
- 9.5.6.4. India: Neurology Clinical Trials Market, by Value Chain, 2020-2034 (USD Billion)
- 9.5.7. Neurology Clinical Trials Market - Malaysia
- 9.5.7.1. Malaysia: Neurology Clinical Trials Market, by Phase, 2020-2034 (USD Billion)
- 9.5.7.2. Malaysia: Neurology Clinical Trials Market, by Study Design, 2020-2034 (USD Billion)
- 9.5.7.3. Malaysia: Neurology Clinical Trials Market, by Indication, 2020-2034 (USD Billion)
- 9.5.7.4. Malaysia: Neurology Clinical Trials Market, by Value Chain, 2020-2034 (USD Billion)
- 9.5.8. Neurology Clinical Trials Market - Japan
- 9.5.8.1. Japan: Neurology Clinical Trials Market, by Phase, 2020-2034 (USD Billion)
- 9.5.8.2. Japan: Neurology Clinical Trials Market, by Study Design, 2020-2034 (USD Billion)
- 9.5.8.3. Japan: Neurology Clinical Trials Market, by Indication, 2020-2034 (USD Billion)
- 9.5.8.4. Japan: Neurology Clinical Trials Market, by Value Chain, 2020-2034 (USD Billion)
- 9.5.9. Neurology Clinical Trials Market - Indonesia
- 9.5.9.1. Indonesia: Neurology Clinical Trials Market, by Phase, 2020-2034 (USD Billion)
- 9.5.9.2. Indonesia: Neurology Clinical Trials Market, by Study Design, 2020-2034 (USD Billion)
- 9.5.9.3. Indonesia: Neurology Clinical Trials Market, by Indication, 2020-2034 (USD Billion)
- 9.5.9.4. Indonesia: Neurology Clinical Trials Market, by Value Chain, 2020-2034 (USD Billion)
- 9.5.10. Neurology Clinical Trials Market - South Korea
- 9.5.10.1. South Korea: Neurology Clinical Trials Market, by Phase, 2020-2034 (USD Billion)
- 9.5.10.2. South Korea: Neurology Clinical Trials Market, by Study Design, 2020-2034 (USD Billion)
- 9.5.10.3. South Korea: Neurology Clinical Trials Market, by Indication, 2020-2034 (USD Billion)
- 9.5.10.4. South Korea: Neurology Clinical Trials Market, by Value Chain, 2020-2034 (USD Billion)
- 9.5.11. Neurology Clinical Trials Market - Australia
- 9.5.11.1. Australia: Neurology Clinical Trials Market, by Phase, 2020-2034 (USD Billion)
- 9.5.11.2. Australia: Neurology Clinical Trials Market, by Study Design, 2020-2034 (USD Billion)
- 9.5.11.3. Australia: Neurology Clinical Trials Market, by Indication, 2020-2034 (USD Billion)
- 9.5.11.4. Australia: Neurology Clinical Trials Market, by Value Chain, 2020-2034 (USD Billion)
- 9.5.12. Neurology Clinical Trials Market - Rest of Asia Pacific
- 9.5.12.1. Rest of Asia Pacific: Neurology Clinical Trials Market, by Phase, 2020-2034 (USD Billion)
- 9.5.12.2. Rest of Asia Pacific: Neurology Clinical Trials Market, by Study Design, 2020-2034 (USD Billion)
- 9.5.12.3. Rest of Asia Pacific: Neurology Clinical Trials Market, by Indication, 2020-2034 (USD Billion)
- 9.5.12.4. Rest of Asia Pacific: Neurology Clinical Trials Market, by Value Chain, 2020-2034 (USD Billion)
- 9.6. Neurology Clinical Trials Market - Middle East & Africa
- 9.6.1. Middle East & Africa: Neurology Clinical Trials Market, by Phase, 2020-2034 (USD Billion)
- 9.6.2. Middle East & Africa: Neurology Clinical Trials Market, by Study Design, 2020-2034 (USD Billion)
- 9.6.3. Middle East & Africa: Neurology Clinical Trials Market, by Indication, 2020-2034 (USD Billion)
- 9.6.4. Middle East & Africa: Neurology Clinical Trials Market, by Value Chain, 2020-2034 (USD Billion)
- 9.6.5. Neurology Clinical Trials Market - Saudi Arabia
- 9.6.5.1. Saudi Arabia: Neurology Clinical Trials Market, by Phase, 2020-2034 (USD Billion)
- 9.6.5.2. Saudi Arabia: Neurology Clinical Trials Market, by Study Design, 2020-2034 (USD Billion)
- 9.6.5.3. Saudi Arabia: Neurology Clinical Trials Market, by Indication, 2020-2034 (USD Billion)
- 9.6.5.4. Saudi Arabia: Neurology Clinical Trials Market, by Value Chain, 2020-2034 (USD Billion)
- 9.6.6. Neurology Clinical Trials Market - UAE
- 9.6.6.1. UAE: Neurology Clinical Trials Market, by Phase, 2020-2034 (USD Billion)
- 9.6.6.2. UAE: Neurology Clinical Trials Market, by Study Design, 2020-2034 (USD Billion)
- 9.6.6.3. UAE: Neurology Clinical Trials Market, by Indication, 2020-2034 (USD Billion)
- 9.6.6.4. UAE: Neurology Clinical Trials Market, by Value Chain, 2020-2034 (USD Billion)
- 9.6.7. Neurology Clinical Trials Market - Israel
- 9.6.7.1. Israel: Neurology Clinical Trials Market, by Phase, 2020-2034 (USD Billion)
- 9.6.7.2. Israel: Neurology Clinical Trials Market, by Study Design, 2020-2034 (USD Billion)
- 9.6.7.3. Israel: Neurology Clinical Trials Market, by Indication, 2020-2034 (USD Billion)
- 9.6.7.4. Israel: Neurology Clinical Trials Market, by Value Chain, 2020-2034 (USD Billion)
- 9.6.8. Neurology Clinical Trials Market - South Africa
- 9.6.8.1. South Africa: Neurology Clinical Trials Market, by Phase, 2020-2034 (USD Billion)
- 9.6.8.2. South Africa: Neurology Clinical Trials Market, by Study Design, 2020-2034 (USD Billion)
- 9.6.8.3. South Africa: Neurology Clinical Trials Market, by Indication, 2020-2034 (USD Billion)
- 9.6.8.4. South Africa: Neurology Clinical Trials Market, by Value Chain, 2020-2034 (USD Billion)
- 9.6.9. Neurology Clinical Trials Market - Rest of Middle East & Africa
- 9.6.9.1. Rest of Middle East & Africa: Neurology Clinical Trials Market, by Phase, 2020-2034 (USD Billion)
- 9.6.9.2. Rest of Middle East & Africa: Neurology Clinical Trials Market, by Study Design, 2020-2034 (USD Billion)
- 9.6.9.3. Rest of Middle East & Africa: Neurology Clinical Trials Market, by Indication, 2020-2034 (USD Billion)
- 9.6.9.4. Rest of Middle East & Africa: Neurology Clinical Trials Market, by Value Chain, 2020-2034 (USD Billion)
- 9.7. Neurology Clinical Trials Market - Latin America
- 9.7.1. Latin America: Neurology Clinical Trials Market, by Phase, 2020-2034 (USD Billion)
- 9.7.2. Latin America: Neurology Clinical Trials Market, by Study Design, 2020-2034 (USD Billion)
- 9.7.3. Latin America: Neurology Clinical Trials Market, by Indication, 2020-2034 (USD Billion)
- 9.7.4. Latin America: Neurology Clinical Trials Market, by Value Chain, 2020-2034 (USD Billion)
- 9.7.5. Neurology Clinical Trials Market - Mexico
- 9.7.5.1. Mexico: Neurology Clinical Trials Market, by Phase, 2020-2034 (USD Billion)
- 9.7.5.2. Mexico: Neurology Clinical Trials Market, by Study Design, 2020-2034 (USD Billion)
- 9.7.5.3. Mexico: Neurology Clinical Trials Market, by Indication, 2020-2034 (USD Billion)
- 9.7.5.4. Mexico: Neurology Clinical Trials Market, by Value Chain, 2020-2034 (USD Billion)
- 9.7.6. Neurology Clinical Trials Market - Brazil
- 9.7.6.1. Brazil: Neurology Clinical Trials Market, by Phase, 2020-2034 (USD Billion)
- 9.7.6.2. Brazil: Neurology Clinical Trials Market, by Study Design, 2020-2034 (USD Billion)
- 9.7.6.3. Brazil: Neurology Clinical Trials Market, by Indication, 2020-2034 (USD Billion)
- 9.7.6.4. Brazil: Neurology Clinical Trials Market, by Value Chain, 2020-2034 (USD Billion)
- 9.7.7. Neurology Clinical Trials Market - Argentina
- 9.7.7.1. Argentina: Neurology Clinical Trials Market, by Phase, 2020-2034 (USD Billion)
- 9.7.7.2. Argentina: Neurology Clinical Trials Market, by Study Design, 2020-2034 (USD Billion)
- 9.7.7.3. Argentina: Neurology Clinical Trials Market, by Indication, 2020-2034 (USD Billion)
- 9.7.7.4. Argentina: Neurology Clinical Trials Market, by Value Chain, 2020-2034 (USD Billion)
- 9.7.8. Neurology Clinical Trials Market - Rest of Latin America
- 9.7.8.1. Rest of Latin America: Neurology Clinical Trials Market, by Phase, 2020-2034 (USD Billion)
- 9.7.8.2. Rest of Latin America: Neurology Clinical Trials Market, by Study Design, 2020-2034 (USD Billion)
- 9.7.8.3. Rest of Latin America: Neurology Clinical Trials Market, by Indication, 2020-2034 (USD Billion)
- 9.7.8.4. Rest of Latin America: Neurology Clinical Trials Market, by Value Chain, 2020-2034 (USD Billion)
10. Competitive Landscape
- 10.1. Expansion and Acquisition Analysis
- 10.1.1. Expansion
- 10.1.2. Acquisitions
- 10.2. Partnerships/Collaborations/Agreements/Exhibitions
11. Company Profiles
- 11.1. Biogen
- 11.1.1. Company Overview
- 11.1.2. Financial Performance
- 11.1.3. Product Benchmarking
- 11.1.4. Recent Development
- 11.2. Charles River Laboratories
- 11.2.1. Company Overview
- 11.2.2. Financial Performance
- 11.2.3. Product Benchmarking
- 11.2.4. Recent Development
- 11.3. Eisai Co., Ltd.
- 11.3.1. Company Overview
- 11.3.2. Financial Performance
- 11.3.3. Product Benchmarking
- 11.3.4. Recent Development
- 11.4. ICON plc
- 11.4.1. Company Overview
- 11.4.2. Financial Performance
- 11.4.3. Product Benchmarking
- 11.4.4. Recent Development
- 11.5. IQVIA
- 11.5.1. Company Overview
- 11.5.2. Financial Performance
- 11.5.3. Product Benchmarking
- 11.5.4. Recent Development
- 11.6. Laboratory Corporation of America Holdings
- 11.6.1. Company Overview
- 11.6.2. Financial Performance
- 11.6.3. Product Benchmarking
- 11.6.4. Recent Development
- 11.7. Medpace Holdings, Inc.
- 11.7.1. Company Overview
- 11.7.2. Financial Performance
- 11.7.3. Product Benchmarking
- 11.7.4. Recent Development
- 11.8. Parexel
- 11.8.1. Company Overview
- 11.8.2. Financial Performance
- 11.8.3. Product Benchmarking
- 11.8.4. Recent Development
- 11.9. Pfizer Inc.
- 11.9.1. Company Overview
- 11.9.2. Financial Performance
- 11.9.3. Product Benchmarking
- 11.9.4. Recent Development
- 11.10. Syneos Health
- 11.10.1. Company Overview
- 11.10.2. Financial Performance
- 11.10.3. Product Benchmarking
- 11.10.4. Recent Development
- 11.11. Thermo Fisher Scientific
- 11.11.1. Company Overview
- 11.11.2. Financial Performance
- 11.11.3. Product Benchmarking
- 11.11.4. Recent Development
